Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies | OncLive

Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies

August 30, 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Checkpoint inhibitors are generating more interest, states Lallas. As far as the T-cell response goes, there are agents which can move the immune process ahead. There are stimulating agents, which are being looked at actively in clinical trials.

Checkpoint inhibitors allow T cells to be activated, as well as the cellular response against those malignancies, which is why they have shown efficacy, explains Lallas.


x